certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
On September 30, 2009, the NNSA announced that about two thirds of the special nuclear material (e.g., plutonium) at LLNL requiring the highest level of security protection had been removed from LLNL. The move was part of NNSA's efforts initiated in October 2006 to consolidate special nuclear material at five sites by 2012, with significantly reduced square footage at those sites by 2017. The federally mandated project intended to improve security and reduce security costs, as part of NNSA's overall effort to transform the Cold War era "nuclear weapons" enterprise into a 21st-century "nuclear security" enterprise. The original date to remove all high-security nuclear material from LLNL, based on equipment capability and capacity, was 2014. NNSA and LLNL then developed a timeline to remove this material earlier, and accelerated the completion date to 2012.
Xenon-135 is a radioactive isotope of xenon, produced as a fission product of uranium. It has a half-life of 9.14 hours and is the most powerful known neutron-absorbing nuclear poison (having a neutron absorption cross-section of about 2 million barns). The overall yield of xenon-135 from fission is 6.3%, without considering any loss by neutron capture. 135Xe exerts a significant effect on nuclear reactor operation (xenon pit). It is discharged to the atmosphere in small quantities by some nuclear power plants.
== External links == "Parathyroid Hormone Receptors: PTH2". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. Receptor,+Parathyroid+Hormone,+Type+2 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
From late 1941 the LRDG co-operated closely with the newly formed Special Air Service (SAS), which also included some Rhodesians. The Rhodesian LRDG patrols transported and supported SAS troops during operations behind Axis lines. The LRDG also maintained a constant "Road Watch" along the Via Balbia on the north coast of Libya, along which almost all Axis road traffic from Tripoli, the main Libyan port, had to travel east. The LRDG set up a watch post about 8 kilometres (5.0 mi) east of the Italian Marble Arch monument, and teams of two men each recorded Axis vehicle and troop movements in shifts throughout the day and night. This information was relayed back to the British commanders in Cairo. Rommel advanced east from January 1942, and won a major victory over the Eighth Army, commanded by Lieutenant-General Neil Ritchie, at the Battle of Gazala in May–June 1942. The Axis soon thereafter captured Tobruk. During the Axis victory at the "Retma Box"—part of the British-devised system whereby isolated, strongly fortified "boxes", each manned by a brigade group, formed the front line—and the subsequent Allied retreat, the Southern Rhodesian Anti-Tank Battery lost five men killed, nine wounded and two missing; 37 were captured. Rommel's advance was stalled in July by the Eighth Army, now headed by General Claude Auchinleck, at the First Battle of El Alamein in western Egypt. Two months later the Rhodesians of the LRDG took part in Operation Bigamy (a.k.a. Operation Snowdrop), an unsuccessful attempt by the SAS and LRDG to raid Benghazi harbour.
=== Pregnancy === Supplementation with a combination of vitamins E and C during pregnancy is not recommended by the World Health Organization. A Cochrane review concluded there was no support for the combination reducing risk of stillbirth, neonatal death, preterm birth, preeclampsia, or any other maternal or infant outcomes, either in healthy women or those considered at risk for pregnancy complications.
Sources: en.wikipedia.org
=== Collaborative history with Pharrell Williams === As a teenage rapper, Malice met music producers Chad Hugo and Pharrell Williams in 1988 and 1990, respectively. Hugo and Williams knew each other and would go on to form the production duo the Neptunes. One day, Pusha T was at Hugo's house and started rapping. Impressed, Williams convinced the brothers to form a rap duo. Clipse's intended debut album, Exclusive Audio Footage (1999), was shelved by Elektra Records; their actual debut Lord Willin' was released by the Neptunes' record label Star Trak Entertainment in 2002. The Neptunes would go on to have production credits on every commercially released studio album by Clipse until the latter's disbandment. Williams claimed to not be on speaking terms with Hugo in 2024 in light of a lawsuit from the latter against him over claims that he was monopolizing the Neptunes name. When asked in 2024 if Clipse worked with Hugo on Let God Sort Em Out, Pusha T denied it. He also responded not being "familiar with" the lawsuit. Clipse stated in 2025 that they still have a strong personal relationship with Hugo, although they differed on whether they missed working with him musically; Pusha T stated that his favorite Clipse album Hell Hath No Fury (2006) was produced entirely by Williams. Malice references the breakup on promotional single "So Be It"—"Ain't no more Neptunes, so P's Saturn."
The MEROPS protease database includes the following ten families of asparagine peptide lyases, which are included in 6 different clans of proteases. Proteolytic enzymes are classified into families based on sequence similarity. Each family includes proteolytic enzymes with homologous sequences and common catalytic type. Clans are groups of proteolytic enzymes families with related structures, where catalytic type is not conserved. *Not yet included in IUBMB recommendations. The ten different families of asparagine peptide lyases are distributed in three different types: Viral coat proteins Autotransporter proteins Intein-containing proteins There are five families of viral coat proteins (N1, N2, N8, N7 and N5), two families of autotransporter proteins (N6 and N4) and three families of intein-containing proteins (N9, N10 and N11).
== Precautions == Californium that bioaccumulates in skeletal tissue releases radiation that disrupts the body's ability to form red blood cells. The element plays no natural biological role in any organism due to its intense radioactivity and low concentration in the environment. Californium can enter the body from ingesting contaminated food or drinks or by breathing air with suspended particles of the element. Once in the body, only 0.05% of the californium will reach the bloodstream. About 65% of that californium will be deposited in the skeleton, 25% in the liver, and the rest in other organs, or excreted, mainly in urine. Half of the californium deposited in the skeleton and liver are gone in 50 and 20 years, respectively. Californium in the skeleton adheres to bone surfaces before slowly migrating throughout the bone. The element is most dangerous if taken into the body. In addition, californium-249 and californium-251 can cause tissue damage externally, through gamma ray emission. Ionizing radiation emitted by californium on bone and in the liver can cause cancer.
The lifespan of a lithium-ion battery is typically defined as the number of full charge-discharge cycles to reach a failure threshold in terms of capacity loss or impedance rise. Manufacturers typically specify cycle life as the number of cycles until capacity falls to 80% of its rated value. Simply storing lithium-ion batteries in the charged state also reduces their capacity and increases the cell resistance (primarily due to the continuous growth of the solid electrolyte interface on the anode). Calendar life describes degradation during storage as well as cycling. Battery cycle life is affected by many different stress factors including temperature, discharge current, charge current, and state of charge ranges (depth of discharge). Because batteries in practical applications are usually only partially charged and discharged, researchers sometimes use cumulative discharge or equivalent full cycles, which sum partial cycles into an equivalent number of full charge–discharge cycles. Batteries stored at a high temperature or a high state of charge often lose their capacities more quickly. Over their lifespan, batteries degrade gradually leading to reduced cyclable charge (a.k.a. Ah capacity) and increased resistance (the latter translates into a lower operating cell voltage).
Sources: en.wikipedia.org
=== Occurrence === Trace amounts of benzene are found in petroleum and coal. It is a byproduct of the incomplete combustion of many materials. For commercial use, until World War II, much of benzene was obtained as a by-product of coke production (or "coke-oven light oil") for the steel industry. However, in the 1950s, increased demand for benzene, especially from the growing polymers industry, necessitated the production of benzene from petroleum. Today, most benzene comes from the petrochemical industry, with only a small fraction being produced from coal. Benzene has been detected on Mars.
== History of drug delivery == Drug delivery is a process of administering therapeutics to treat human diseases. The first drug delivery system is often dated to the 1950s, when Smith Kline & French Laboratories introduced the Spansule technology. Between 1950s and 1980s, there were four drug release systems developed for oral and transdermal applications: dissolution, diffusion, osmosis, and ion-exchange controlled release. Later in the 1980s, the Lupron Depot technology further advanced the field by offering zero-order and long-term release systems. The intranasal route gained interest towards the end of the 20th century with treating cardiovascular and respiratory diseases. During the late 1980s, William Frey II studied the intranasal route for treating brain diseases. Ever since, it has become a potential route for nose-to-brain delivery.
Special care must be taken when supplementing the medium with FBS (fetal bovine serum), as it also contains small metabolites used for the biosynthesis of nucleosides. The use of dialyzed FBS is therefore advisable when defined labeling of all nucleosides is desired.
== External links == Clinical trial number NCT03500549 for "Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)" at ClinicalTrials.gov Clinical trial number NCT03525613 for "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration " at ClinicalTrials.gov Clinical trial number NCT03525600 for "Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration " at ClinicalTrials.gov
==== A, Short Order ==== The Unitized Group Ration – A, Short Order (UGR-A SO) consists of meals intended to supplement the UGR-A and expand available food options or feed larger groups, especially where alternate dining facilities or existing meal options are unavailable. Most UGR-A SO meals are based on fast food, pub food, and finger food. The UGR-A SO has the same kilocalorie amount, storage, and minimum shelf life as the regular UGR-A.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.